Open access
Open access
Powered by Google Translator Translator

Oncology (all articles)

Opinion | Irreconcilable differences: the divorce between response rates, progression-free survival, and overall survival

20 Mar, 2023 | 13:45h | UTC

Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival – Journal of Clinical Oncology

 

RCT | Sotorasib vs. docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation

20 Mar, 2023 | 13:10h | UTC

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)

 

Commentary on Twitter

 

FDA issues new information on cases of squamous cell carcinoma and lymphomas around breast implants

16 Mar, 2023 | 13:28h | UTC

Summary: The US Food and Drug Administration (FDA) has provided an update on reports of squamous cell carcinoma (SCC) in the scar tissue (capsule) that forms around breast implants. The FDA is aware of 19 cases of SCC in the capsule around the breast implant from published literature, including 3 reports of deaths from the disease.

While the FDA continues to believe that occurrences of SCC in the capsule around the breast implant may be rare, the cause, incidence, and risk factors remain unknown. Health care providers and people who have or are considering breast implants should be aware that cases of SCC and various lymphomas in the capsule around the breast implant have been reported to the FDA and in the literature.

The FDA continues to ask health care providers and people with breast implants to report cases of SCC, lymphomas, or any other cancers around breast implants.

FDA Safety Communication: Reports of Squamous Cell Carcinoma (SCC) in the Capsule Around Breast Implants – FDA Safety Communication – U.S. Food & Drug Administration

Commentary: FDA Issues Safety Communication on Reports of Squamous Cell Carcinoma in the Capsule Around Breast Implants – The ASCO Post

Related:

FDA Report: 660 Cases of Breast Implant-Associated Anaplastic Large Cell Lymphoma

Study: Long-term Outcomes of Silicone Breast Implants

 

M-A | Low-intensity follow-up after cancer surgery does not reduce patient satisfaction or well-being

16 Mar, 2023 | 13:10h | UTC

Oncological surgery follow-up and quality of life: meta-analysis – British Journal of Surgery

 

RCT | Patient-reported outcomes 12 years after different treatments for localized prostate cancer

15 Mar, 2023 | 15:24h | UTC

Summary: The article reports on a study that evaluated patient-reported outcomes of 1,643 participants in the ProtecT trial over a period of 7 to 12 years to assess the long-term functional and quality-of-life impacts of prostatectomy, radiotherapy with neoadjuvant androgen deprivation, and active monitoring for localized prostate cancer detected by PSA screening.

The study found that generic quality-of-life scores were similar among the randomized groups over 7 to 12 years. However, although the prostatectomy group had a lower incidence of nocturia, they showed a higher incidence of urinary incontinence and sexual dysfunction compared to the radiotherapy and active monitoring groups. The radiotherapy group had a higher incidence of fecal leakage compared to the other groups.

The study provides evidence that helps patients and their clinicians assess the trade-offs between treatment harms and benefits and make better-informed treatment decisions.

Article: Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment – NEJM Evidence

Original Study: RCT | Localized prostate cancer treatment options have similar 15-year survival outcomes

 

Consensus Statement | Best current practice and research priorities in active surveillance for prostate cancer

15 Mar, 2023 | 15:11h | UTC

Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer—A Report of a Movember International Consensus Meeting – European Urology Oncology

 

RCT | Nirogacestat for desmoid tumors

15 Mar, 2023 | 14:57h | UTC

Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Nirogacestat Improves Outcomes for Patients With Desmoid Tumors – Memorial Sloan Kettering Cancer Center

 

Commentary on Twitter

 

Review | Surveillance strategies following curative resection and non-operative approach of rectal cancer: how and how long?

15 Mar, 2023 | 14:59h | UTC

Surveillance strategies following curative resection and non-operative approach of rectal cancer: How and how long? Review of current recommendations – World Journal of Gastrointestinal Surgery

 

M-A | Laparoscopic vs. open distal gastrectomy for locally advanced gastric cancer

15 Mar, 2023 | 14:52h | UTC

Laparoscopic vs. open distal gastrectomy for locally advanced gastric cancer: A systematic review and meta-analysis of randomized controlled trials – Frontiers in Surgery

Related:

Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: 5-Year Outcomes of the KLASS-02 Randomized Clinical Trial – JAMA Surgery

Short-and long-term outcomes of laparoscopic versus open gastrectomy in patients with gastric cancer: a systematic review and meta-analysis of randomized controlled trials – World Journal of Surgical Oncology

Laparoscopic versus open distal gastrectomy for gastric cancer: A systematic review and meta-analysis – Surgery

Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Outcomes From the CLASS-01 Randomized Clinical Trial – JAMA Surgery

Laparoscopic Versus Open Gastrectomy for Gastric Cancer (LOGICA): A Multicenter Randomized Clinical Trial – Journal of Clinical Oncology

Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer: The CLASS02 Multicenter Randomized Clinical Trial – JAMA Oncology

Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial – The Lancet Gastroenterology & Hepatology

Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KLASS-01 Randomized Clinical Trial – JAMA Oncology

 

Cohort Study | Higher ultra-processed food consumption linked to increased cancer incidence and mortality

15 Mar, 2023 | 14:48h | UTC

Ultra-processed food consumption, cancer risk and cancer mortality: a large-scale prospective analysis within the UK Biobank – eClinicalMedicine

News Release: Ultra-processed foods may be linked to increased risk of cancer – Imperial College London

Commentary: Expert reaction to study looking at ultra-processed foods and risk of different cancers – Science Media Centre

Related:

Association of ultra-processed food consumption with colorectal cancer risk among men and women: results from three prospective US cohort studies – The BMJ

Joint association of food nutritional profile by Nutri-Score front-of-pack label and ultra-processed food intake with mortality: Moli-sani prospective cohort study – The BMJ

Association between consumption of ultra-processed foods and all cause mortality: SUN prospective cohort study – The BMJ

Ultra-processed food intake and risk of cardiovascular disease: prospective cohort study (NutriNet-Santé) – The BMJ

 

Scanxiety among adults with cancer: a scoping review to guide research and interventions

14 Mar, 2023 | 13:55h | UTC

Summary: The article presents a scoping review of existing literature on scanxiety, which refers to the anxiety and distress experienced by cancer patients before and after medical imaging scans. The authors identified and synthesized findings from 36 articles on scanxiety among adults diagnosed with current or prior cancer.

The authors observed that scanxiety is a prevalent issue throughout the cancer continuum and may be linked to various factors related to the procedure itself or the uncertainty surrounding the possible outcomes of the scans.

The waiting period between the scan procedure and receipt of the results was described as particularly stressful, with participants reporting feeling overwhelmed by negative thoughts and fears about the potential outcomes of the scan. Some participants even found it difficult to focus on daily activities or responsibilities during this time.

The authors suggest that implementing supportive measures during scan experiences, including examining the waiting period between scans and scan results, could enhance the well-being for individuals with cancer who are going through different stages of treatment.

Article: Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions – Cancers

 

Press release | New technique reduces postoperative complications in prostate cancer surgery

14 Mar, 2023 | 13:33h | UTC

Press release: New technique reduces postoperative complications in prostate cancer surgery – European Association of Urology

 

Feasibility and efficacy of microwave ablation in the treatment of papillary thyroid microcarcinoma: a prospective cohort study

14 Mar, 2023 | 13:30h | UTC

Microwave Ablation for Papillary Thyroid Microcarcinoma with and without US-detected Capsule Invasion: A Multicenter Prospective Cohort Study – Radiology (link to abstract – $ for full-text)

 

Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer

14 Mar, 2023 | 13:21h | UTC

Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer – Cochrane Library

Summary: Dose-escalated radiotherapy for curative treatment in men with clinically localized prostate cancer – Cochrane Library

 

RCT | Localized prostate cancer treatment options have similar 15-year survival outcomes

13 Mar, 2023 | 15:12h | UTC

Summary: The study followed 1643 men diagnosed with localized prostate cancer (diagnosed by screening with PSA) in the United Kingdom between 1999 and 2009 who were randomly assigned to receive active monitoring, prostatectomy, or radiotherapy.

After a median follow-up of 15 years, the study found that while prostatectomy and radiotherapy decreased metastasis, local progression, and the need for long-term androgen deprivation therapy, death from prostate cancer was low regardless of the treatment assigned, with 17 deaths (3.1%) in the active-monitoring group, 12 deaths (2.2%) in the prostatectomy group, and 16 (2.9%) deaths in the radiotherapy group (P=0.53). Additionally, the study found that overall deaths were similar between the groups.

The authors suggest that the choice of therapy for localized prostate cancer involves weighing the benefits and harms associated with each treatment option.

Article: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Delaying treatment for localised prostate cancer does not increase mortality risk, trial shows – University of Bristol

 

Commentary on Twitter

 

Hospitalist comanagement reduces patients’ length of stay and improves oncologist experience, preliminary evidence suggests

13 Mar, 2023 | 14:33h | UTC

Outcomes on an inpatient oncology service after the introduction of hospitalist comanagement – Journal of Hospital Medicine (link to abstract – $ for full-text)

News Release: Involving hospitalists in inpatient cancer care reduces patient stays, oncologist stress – Yale School of Medicine

 

Cohort Study | Clinical associations and classification of immune checkpoint inhibitor‐induced cutaneous toxicities

10 Mar, 2023 | 14:09h | UTC

Clinical associations and classification of immune checkpoint inhibitor‐induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients – British Journal of Dermatology

 

M-A | Supplemental breast cancer screening in women with dense breasts and negative mammography

10 Mar, 2023 | 14:12h | UTC

Supplemental Breast Cancer Screening in Women with Dense Breasts and Negative Mammography: A Systematic Review and Meta-Analysis – Radiology (link to abstract – $ for full-text)

News Release: Breast MRI effective at detecting cancer in dense breasts – Radiological Society of North America

Commentary: Study Finds Breast MRI Superior vs Other Supplementary Screening Tests for Detecting Breast Cancer in Patients With Dense Breasts – The ASCO Post

 

Commentary on Twitter

 

Consensus Recommendations | Spinal tumors

9 Mar, 2023 | 14:15h | UTC

Spinal tumours: recommendations of the Polish Society of Spine Surgery, the Polish Society of Oncology, the Polish Society of Neurosurgeons, the Polish Society of Oncologic Surgery, the Polish Society of Oncologic Radiotherapy, and the Polish Society of Orthopaedics and Traumatology – European Spine Journal

 

M-A | Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer

9 Mar, 2023 | 14:06h | UTC

Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials – The Breast

 

Practice Guide | Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing

9 Mar, 2023 | 14:04h | UTC

Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide – CA: A Cancer Journal for Clinicians

 

RCT/extended follow-up | Lenvatinib plus pembrolizumab vs. sunitinib in patients with advanced renal cell carcinoma

9 Mar, 2023 | 14:03h | UTC

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study – The Lancet Oncology (link to abstract – $ for full-text)

Original Study: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 

Consensus Paper | Management of patients with advanced prostate cancer

7 Mar, 2023 | 13:02h | UTC

Management of patients with advanced prostate cancer. Metastatic and/or castration resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 – European Journal of Cancer

 

Guideline | Diagnosis, management, and follow-up of the incidentally discovered adrenal mass

6 Mar, 2023 | 14:16h | UTC

Canadian Urological Association guideline: Diagnosis, management, and follow up of the incidentally discovered adrenal mass – Canadian Medical Association Journal

 

Phase 2 RCT | Neoadjuvant–adjuvant pembrolizumab improves event-free survival vs. adjuvant-only therapy in advanced melanoma

6 Mar, 2023 | 14:11h | UTC

Summary:

This phase 2 clinical trial evaluated whether giving pembrolizumab before and after surgery (neoadjuvant-adjuvant therapy) would increase event-free survival in patients with resectable stage III or IV melanoma, compared to adjuvant therapy alone. The trial involved 313 patients, with 154 in the neoadjuvant-adjuvant group and 159 in the adjuvant-only group.

At a median follow-up of 14.7 months, the neoadjuvant-adjuvant group had significantly longer event-free survival than the adjuvant-only group, with similar rates of adverse events between groups, suggesting that pembrolizumab given both before and after surgery may be an effective treatment option for these patients.

 

Article: Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Neoadjuvant immunotherapy improves outlook in high-risk melanoma – MD Anderson Cancer Center

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.